NEW YORK (GenomeWeb News) – Abbott Laboratories today reported that its fourth quarter 2013 molecular diagnostics sales were flat year over year as its overall diagnostics sales increased 6 percent.

The firm posted MDx sales of $131 million for the quarter, flat with Q4 2012. It said that foreign exchange trimmed nearly 1 percent off its MDx revenues for the quarter. However, its international MDx sales were up around 10 percent on an operational basis, driven by "continued strong growth in infectious disease testing, particularly in emerging markets."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
15
Sponsored by
Parabase

This webinar will discuss the benefits of a rapid targeted next-generation sequencing (TNGS) panel, using dried blood spots, for second-tier newborn metabolic and hearing loss screening and its immediate utility for high-risk diagnostic testing in the neonatal intensive care unit.